Most Read

As per the agreement terms, Orbit will discover peptide leads specific to targets related to certain tumours by deploying its bead-based peptide display engine. Orbit Discovery CEO Dr

An engineered interleukin-2 (IL-2)-diphtheria toxin fusion protein, Lymphir is intended for relapsed or refractory CTCL patients following treatment with a minimum of one systemic therapy previously. As per

As per the agreement, Procaps will be responsible for activities related to registration, branding, marketing along with commercialisation throughout Latin America. Procaps submitted an initial set of eight

Under the agreement, Maruho will be responsible for the development and commercialisation of Qbrexza in South Korea, Brunei, Cambodia, Indonesia, Hong Kong, Macau, Vietnam, Malaysia, Philippines, Thailand, Myanmar,

The latest move comes after signing an exclusive licence agreement with HK inno.N in November 2020. The agreement granted sublicensing rights to UITC for developing, marketing, and manufacturing

The latest move is aimed at sharing the government’s objective to make obesity care accessible to patients with high unmet medical need. Through a controlled and limited launch,

The company will utilise proceeds from the round for further developing its technology platform to accelerate its lead programmes to clinical stage. The participants in the financing round

The approval was granted to the company’s Specialty Generics segment, operating as SpecGx. Mallinckrodt started selling the product after securing approval, which happened the day after the expiration

A small molecular compound and a novel type of calcimimetics discovered by Mitsubishi Tanabe Pharma Corporation, Orkedia Tablets suppresses parathyroid hormone (PTH) secretion as it acts on the